Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements

Sarah R. DiNapoli(Howard Hughes Medical Institute), Bert Vogelstein(Howard Hughes Medical Institute), Evangeline Watson(Howard Hughes Medical Institute), Marco Dal Molin(Johns Hopkins University), Jacqueline Douglass(Howard Hughes Medical Institute), Alexander H. Pearlman(Johns Hopkins University), Joshua D. Cohen(Howard Hughes Medical Institute), Maria Popoli(Johns Hopkins University), Maximilian F. Konig(Johns Hopkins Medicine), Katharine M. Wright(Johns Hopkins University), Suman Paul(Johns Hopkins University), Nikita Marcou(Howard Hughes Medical Institute), Kathleen L. Gabrielson(Johns Hopkins University), Kenneth W. Kinzler(Johns Hopkins University), Brian J. Mog(Howard Hughes Medical Institute), Sandra B. Gabelli(Johns Hopkins University), Tushar D. Nichakawade(Howard Hughes Medical Institute), Nicolas Wyhs(Johns Hopkins University), Emily Han-Chung Hsiue(Howard Hughes Medical Institute), Shibin ZHOU(Johns Hopkins University), Michael S. Hwang(Howard Hughes Medical Institute), Jin Liu(Howard Hughes Medical Institute), Tolulope O. Awosika(Howard Hughes Medical Institute), Nickolas Papadopoulos(Johns Hopkins University), Qiang Liu(Howard Hughes Medical Institute), Jiaxin Ge(Howard Hughes Medical Institute), Stephanie Glavaris(Sidney Kimmel Comprehensive Cancer Center), Drew M. Pardoll(Johns Hopkins University), P. Aitana Azurmendi(Howard Hughes Medical Institute)
Journal of Clinical Investigation
January 15, 2026
Cited by 0


Related Papers